Valuation: Royalty Pharma plc

Market Cap 27.3B 23.39B 21.88B 20.03B 37.59B 2,612B 38.09B 259B 101B 1,312B 103B 100B 4,340B P/E 2026 *
24.9x
P/E 2027 * 17.4x
Enterprise Value 36.41B 31.19B 29.18B 26.71B 50.13B 3,484B 50.8B 345B 134B 1,750B 137B 134B 5,788B EV / Sales 2026 *
10.4x
EV / Sales 2027 * 9.59x
Free-Float
72.41%
Yield 2026 *
1.65%
Yield 2027 * 1.74%
1 week+3.92%
Current month+2.86%
1 month+3.94%
1 month 50.08
Extreme 50.08
52.98
Manager TitleAgeSince
Chief Executive Officer 62 01/01/1996
Director of Finance/CFO 44 01/01/2010
Chief Tech/Sci/R&D Officer - 21/09/2023
Director TitleAgeSince
Chairman 62 01/04/2020
Director/Board Member 68 11/02/2020
Director/Board Member 63 16/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
+3.92%+3.92% - - 27.3B
+0.88%+6.38%+76.40%+126.75% 1,119B
+1.07%+3.80%+50.73%+62.78% 651B
+1.20%+6.21%+25.81%+78.74% 468B
+1.02%+5.77%+43.63%+48.43% 374B
+0.85%+4.07%+24.97%+40.58% 302B
+1.26%+6.81%+2.27%+14.41% 259B
+1.88%+5.81%+49.57%+70.53% 238B
+1.59%+2.09%-17.33%-52.62% 208B
+1.87%+5.61%+27.32%+91.38% 181B
Average +1.29%+4.97%+31.49%+53.44% 422.21B
Weighted average by Cap. +1.14%+5.09%+44.26%+72.65%

Financials

2026 *2027 *
Net sales 3.5B 3B 2.8B 2.57B 4.81B 335B 4.88B 33.11B 12.91B 168B 13.13B 12.84B 556B 3.81B 3.26B 3.05B 2.79B 5.25B 364B 5.31B 36.07B 14.07B 183B 14.3B 13.99B 606B
Net income 1.47B 1.26B 1.18B 1.08B 2.02B 141B 2.05B 13.92B 5.43B 70.65B 5.52B 5.4B 234B 1.79B 1.54B 1.44B 1.32B 2.47B 172B 2.5B 16.99B 6.63B 86.24B 6.74B 6.59B 285B
Net Debt 9.11B 7.8B 7.3B 6.68B 12.54B 872B 12.71B 86.27B 33.64B 438B 34.21B 33.46B 1,448B 9.22B 7.9B 7.39B 6.76B 12.69B 882B 12.86B 87.3B 34.05B 443B 34.62B 33.87B 1,466B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Employees
-
Date Price Change
21/08/26 €52.45 +3.92%
14/08/26 €50.47 -1.12%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
61.31USD
Average target price
64.75USD
Spread / Average Target
+5.61%

Quarterly revenue - Rate of surprise